Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-01-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel, specifically the hiring of Mr. Gu Wei as the company's Executive Vice President. It includes details about the nomination, approval by the board, and a brief biography of the appointee. There is no financial data, report, or regulatory filing referenced beyond the appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-01-27 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司回购注销部分2022年限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the repurchase and cancellation of restricted stock under a 2022 stock incentive plan by the company. It details the legal basis, approval procedures, stock quantities, prices, and funding sources for the repurchase and cancellation. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a specific corporate action involving stock repurchase and cancellation. This fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal document related to corporate governance and stock incentive plan adjustments, not a standalone audit report or capital/financing update. The document length is short (2714 characters) and it is not an announcement of a report publication but a substantive legal opinion letter. Therefore, the classification is RNS with high confidence.
2025-01-27 Chinese
益丰药房关于回购注销2022年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under the company's 2022 restricted stock incentive plan. It details the number of shares repurchased, prices, approvals, legal opinions, and the impact on share structure. It is not a full financial report, earnings release, or management discussion. It is a specific corporate action announcement related to share repurchase and cancellation of restricted stock. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2025-01-27 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2025年第一次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of a company's 2025 first extraordinary shareholders meeting. It details the legal compliance of the meeting process, qualifications of attendees, and voting outcomes. The document is not a financial report, earnings release, or management discussion, but a legal certification related to a shareholders meeting. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality and procedures. Given the nature of the document as a legal opinion on a shareholders meeting, it best fits under Regulatory Filings (RNS), which covers compliance documents and legal attestations that do not fit other categories. The document length is under 5,000 characters and is a standalone legal opinion, not a report publication announcement or a proxy solicitation. Therefore, the classification is RNS with high confidence.
2025-01-27 Chinese
益丰药房关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from the board of directors of 益丰大药房连锁股份有限公司 regarding the repurchase and cancellation of part of the restricted stocks under the 2022 restricted stock incentive plan. It notifies creditors about the repurchase and the related reduction in registered capital, and provides details on how creditors can claim debts or request guarantees within a specified period. The document is an official notice about a corporate action involving share repurchase and capital change, but it is not a full financial report or detailed analysis. It is not an earnings release, annual report, or management report. The key activity is the repurchase and cancellation of shares, which fits the category of Transaction in Own Shares (POS). The document length is short (1253 characters), and it contains substantive information about the transaction, not just a report publication announcement or regulatory filing. Therefore, the correct classification is POS.
2025-01-27 Chinese
益丰药房第五届监事会第九次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement of a resolution passed at the ninth meeting of the fifth Supervisory Board of Yifeng Pharmacy Chain Co., Ltd. It details the decision to repurchase and cancel certain restricted shares from the 2022 restricted stock incentive plan due to employee departures or demotions. The document includes voting results and confirms compliance with relevant laws and company regulations. It is not a full financial report, audit, or earnings release, nor is it a presentation or call transcript. It is a corporate governance-related announcement about share repurchase and cancellation, which fits best under the category of Transaction in Own Shares (POS). The document length is short and it contains specific details about the transaction rather than just announcing a report or meeting results, so it is not RPA or DVA. Therefore, the classification is POS with high confidence.
2025-01-27 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.